Stock Expert AI

The Obesity ETF (SLIM) ETF Analysis

The Obesity ETF (SLIM) is a non-diversified equity ETF with $0.01 billion in assets under management and an expense ratio of 0.35%. SLIM provides exposure to companies positioned to profit from servicing the obese, including those in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, supplements, and plus-sized apparel. The fund seeks to track the Solactive Obesity Index, offering a targeted investment in a specific health and consumer trend.

The Obesity ETF (SLIM) ETF — Price, Holdings & Analysis

The Obesity ETF (SLIM) is a non-diversified equity ETF with $0.01 billion in assets under management and an expense ratio of 0.35%. SLIM provides exposure to companies positioned to profit from servicing the obese, including those in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, supplements, and plus-sized apparel. The fund seeks to track the Solactive Obesity Index, offering a targeted investment in a specific health and consumer trend.

ETF Overview

The investment seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The fund invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. It is non-diversified.
SLIM aims to capture the performance of companies globally that are expected to benefit from the increasing prevalence of obesity. The ETF tracks the Solactive Obesity Index, investing at least 80% of its net assets in its constituent stocks. This targeted approach results in a concentrated portfolio, with a significant allocation to the healthcare sector (91.9%). The fund's top holdings include Novo Nordisk A/S ADR (19.95%), a major player in diabetes and obesity care, and DexCom Inc (13.38%), a company specializing in continuous glucose monitoring systems. Other significant holdings include Fresenius Medical Care AG & Co. KGaA (8.64%) and Insulet Corp (6.27%). SLIM offers investors a way to invest in companies involved in addressing and managing obesity and related conditions.

Risk Metrics

SLIM's non-diversified nature and concentrated sector allocation introduce specific risks. The heavy weighting in healthcare (91.9%) means the fund's performance is highly correlated with the performance of that sector. A significant portion of the fund is allocated to its top holdings, with Novo Nordisk A/S ADR comprising nearly 20% of the portfolio, indicating concentration risk. The fund's beta of 0.70 suggests it is less volatile than the overall market. The expense ratio of 0.35% will create a drag on performance over time, although this is in line with similar thematic ETFs. Investors should be aware of these factors when considering an investment in SLIM. Past performance does not guarantee future results.

Expense Ratio

0.35%

Top Holdings

Sector Allocation

  • Healthcare: 91.9%
  • Consumer Defensive: 4.3%
  • Consumer Cyclical: 3.9%

Dividend Yield

0.57%
  • <a href="/etf/rwde">Direxion MSCI Developed Over Emerging Markets ETF (RWDE)</a> — 0.53% expense ratio
  • <a href="/etf/fine">Themes European Luxury ETF (FINE)</a> — 0.35% expense ratio
  • <a href="/etf/mj">Amplify Alternative Harvest ETF (MJ)</a> — 0.75% expense ratio
  • <a href="/etf/defa">iShares Adaptive Currency Hedged MSCI EAFE ETF (DEFA)</a> — 0.35% expense ratio
  • <a href="/etf/psmm">Invesco Moderately Conservative Multi-Asset Allocation ETF (PSMM)</a> — 0.35% expense ratio
  • <a href="/etf/gxg">Global X - MSCI Colombia ETF (GXG)</a> — 0.62% expense ratio
  • <a href="/etf/omfs">Invesco Russell 2000 Dynamic Multifactor ETF (OMFS)</a> — 0.39% expense ratio
  • <a href="/etf/xhb">State Street SPDR S&P Homebuilders ETF (XHB)</a> — 0.35% expense ratio

Risk Metrics

  • Beta: 0.70

Questions & Answers

What is SLIM and what does it track?

The Obesity ETF (SLIM) seeks to replicate the performance of the Solactive Obesity Index. This index is designed to track companies globally that are positioned to profit from servicing the obese population. These companies include those involved in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, weight loss supplements, and plus-sized apparel. SLIM is a non-diversified fund, meaning it invests in a smaller number of companies compared to broad market ETFs, leading to potentially higher volatility.

What is the expense ratio for SLIM?

The expense ratio for SLIM is 0.35%. This means that for every $10,000 invested in the fund, $35 is deducted annually to cover operating expenses. While it's difficult to determine a precise category average for such a niche thematic ETF, the expense ratio is comparable to other specialized equity ETFs. the may be worth researching expense ratio as a factor impacting the overall return of the fund over time.

What are the top holdings in SLIM?

SLIM's top holdings reflect its focus on companies involved in obesity-related products and services. As of 2026-03-15, the top three holdings are Novo Nordisk A/S ADR (19.95%), a leading pharmaceutical company in diabetes and obesity care; DexCom Inc (13.38%), which specializes in continuous glucose monitoring systems; and Fresenius Medical Care AG & Co. KGaA (8.64%), a provider of dialysis products and services. These holdings constitute a significant portion of the fund's assets, highlighting the concentrated nature of the ETF.

Is SLIM a good long-term investment?

Whether SLIM is a suitable long-term investment depends on an individual's investment goals and risk tolerance. The fund offers targeted exposure to a specific theme, which can lead to concentrated risk. SLIM's performance will be influenced by the growth of the obesity-related market and the success of its constituent companies. With a beta of 0.70, it has historically been less volatile than the broader market. Investors should carefully consider these factors and conduct thorough research before investing. Past performance does not guarantee future results.

How does SLIM compare to similar ETFs?

SLIM is unique in its specific focus on companies profiting from the obesity market. While there aren't many directly comparable ETFs, some broader healthcare ETFs may have overlapping holdings. SLIM's expense ratio of 0.35% is competitive within the thematic ETF space. With AUM of $0.01 billion, SLIM is a relatively small ETF, which can impact liquidity and trading costs. Investors should compare SLIM's strategy and holdings with other healthcare or thematic ETFs to determine the best fit for their portfolio.

Does SLIM pay dividends?

Yes, SLIM pays dividends. The current dividend yield for SLIM is 0.57%. This means that for every $100 invested in the fund, investors can expect to receive $0.57 in dividend payments annually. The dividend yield may fluctuate based on the performance of the underlying holdings and the fund's distribution policy. Investors seeking income may find this dividend yield attractive, but should also consider the fund's overall investment strategy and risk profile.